[Hong Kong, October 11, 2022] Great Bay Bio (hereinafter referred to as “GBB”) today announces the official launch of

[HONG KONG, September 13, 2022] Great Bay Bio (hereinafter referred to as “GBB”) is pleased to announce today the comp

[HONG KONG, April 6, 2022] Recently, Microsoft Accelerator officially announced the “2022 Spring Semester List” and Great Bay Bio (GBB) was successfully listed on the “medical and lifescience” group.

[HONG KONG, January 28, 2022] Great Bay Bio Group Limited (hereinafter referred to as“GBB”), an AI-enabled biotechnology company, announced today that it has formeda strategic alliance with Cheerland Life Science (hereinafter referred to as“Cheerland”), j

[HONG KONG, January 25, 2022] Great Bay Bio Group Limited (hereinafter referred to as “GBB”), an AI-enabled biotechnology company, announced today that it has formed a strategic alliance with ChemPartner, further strengthening both company’s value proposi

[HONG KONG,December 31, 2021] Great Bay Bio (GBB), an AI-enabled biotechnology company,announces the participation of FutureX Capital in its Series A roundfundraising.

Taili Biotech, a wholly-owned domestic subsidiary of Great Bay Bio (GBB), won the Special Prize of NVIDIA Start-up Final Showcase. Dr. Deng Xinyu, CTO of GBB, was invited to participate in the NVIDIA 2021 Data Lake Conference and presented a live broadcas

[HONG KONG, December 1, 2021] Great Bay Bio (hereinafter referred to as “GBB”) is pleased to announce today the completion of its near USD 10M series A fundraising led by Proxima Ventures.